Anticipating biological threats from advanced AI

Advanced artificial intelligence is reshaping biology and medicine, but it also brings biosecurity risks that need careful attention. This article is for anyone curious about how AI tools might be misused in life sciences—and what proactive steps are being taken to prevent that from happening. You'll learn what the concerns are, why they matter, and how safeguards are being put in place before problems arise.

Why AI in Biology Is Both Promising and Risky

AI systems are increasingly capable of helping scientists understand proteins, design molecules, and accelerate drug discovery. For researchers and doctors, this means faster breakthroughs: new treatments developed in months instead of years, better diagnostics, and deeper insight into how diseases work at the molecular level.

But the same capabilities that help scientists could, in theory, help bad actors. An AI system that can suggest how to engineer a biological organism could, if misused, provide information that enables harm. This is the core of the biosecurity challenge: the technology doesn't distinguish between a well-intentioned researcher and someone with malicious goals. That's why responsibility falls on the companies building these systems to anticipate risks early.

Taking a Proactive Approach Rather Than a Reactive One

A key theme in AI safety today is anticipation—assessing what a system can do before it's widely deployed, rather than waiting for misuse to occur and responding afterward.

In practice, this means:

• Testing capabilities before release. Teams evaluate whether a model could produce information that poses biological risks, using structured evaluations designed to probe for dangerous outputs.
• Setting clear thresholds. Companies define in advance what level of capability would be considered unacceptable, so decisions about deployment are based on evidence rather than guesswork.
• Updating as models improve. Because AI capabilities evolve quickly, risk assessments aren't one-time events. They're repeated as new versions of models are developed.

This proactive stance mirrors practices in other high-stakes industries, such as aviation or pharmaceuticals, where safety testing happens throughout development—not just after something goes wrong.

What Safeguards Look Like in Practice

Preventing misuse involves multiple layers of protection working together:

Refusals and guardrails. AI systems can be trained to decline requests that clearly ask for dangerous biological information, such as instructions for engineering pathogens. Users asking legitimate research questions get helpful answers; requests that cross safety lines do not.

Red-teaming. Experts deliberately try to get a system to produce harmful outputs—stress-testing it the way security professionals test computer systems. Findings from these exercises feed directly back into improvements.

Access controls. More powerful capabilities can be limited to vetted users, such as academic or institutional researchers, rather than being available to everyone without checks.

Collaboration with outside experts. AI developers increasingly work with biosecurity specialists, government agencies, and independent researchers who understand biological risks far better than a typical machine learning engineer does. External input helps catch blind spots that internal teams might miss.

None of these measures is perfect on its own. The goal is defense in depth: several overlapping safeguards, so a weakness in one layer is covered by another.

Why This Matters Beyond the Lab

Biosecurity in the AI era isn't just a technical issue—it's a public trust issue. People are more likely to benefit from AI in medicine if they believe the technology is being handled responsibly. Transparency about risk assessments, even in general terms, helps build that confidence.

There's also an international dimension. Biological threats don't respect borders, so best practices developed by leading AI labs often influence policy discussions, industry standards, and eventually regulation. Early voluntary safeguards can shape how the whole field matures.

At the same time, it's worth staying realistic. The actual risk from today's AI systems in biology is debated among experts, and assessments are still relatively new. What's clear is that the direction of capability growth makes early attention to safety essential—the right time to build safeguards is while the stakes are still manageable.

The Road Ahead

The intersection of AI and biology will only grow more significant. As models become more capable of reasoning about life sciences, the safeguards around them need to keep pace. The proactive approach—testing capabilities, setting thresholds, layering defenses, and working with domain experts—represents a sensible foundation, but it will require ongoing refinement.

For the rest of us, the takeaway is straightforward: AI's role in biology is a genuine opportunity, and the risks are being taken seriously by the organizations building these systems. Staying informed, and supporting transparency from AI developers, helps ensure that the benefits reach society while the dangers stay contained.

Meta description: How AI firms assess biosecurity risks in biology and medicine, and the safeguards they use to prevent misuse before it happens.

Tags: AI safety, biosecurity, AI in medicine, responsible AI, risk assessment

Featured image: A friendly abstract illustration of a glowing neural network gently intertwined with a stylized DNA helix and a shield outline, in soft blues and greens—no people, logos, or text.